Axcess News – Lifestyle
Author:
Sionna Therapeutics, Inc.
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
April 27, 2026
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium
April 7, 2026
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
March 6, 2026
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences
March 5, 2026